Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2021-12-31 | 81255000 | dkk |
| ifrs-full:Assets | 2020-12-31 | 140286000 | dkk |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2021-01-01 | 2021-12-31 | 24254000 | dkk |
| ifrs-full:Revenue | 2020-01-01 | 2020-12-31 | 23204000 | dkk |
XML
See the xml submitted here:
XML: INVALID
Separator
The full data:
<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
xmlns="http://www.w3.org/1999/xhtml"
xmlns:arr="http://xbrl.dcca.dk/arr"
xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12"
xmlns:cmn="http://xbrl.dcca.dk/cmn"
xmlns:sob="http://xbrl.dcca.dk/sob"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:BIO="http://xbrl.bioporto.com/2021-12-31"
xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2020-03-16/ifrs-full"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
xmlns:mrv="http://xbrl.dcca.dk/mrv"
xmlns:fsa="http://xbrl.dcca.dk/fsa"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:gsd="http://xbrl.dcca.dk/gsd"
xmlns:xlink="http://www.w3.org/1999/xlink"
id="DKGAAP"
xml:lang="en">
<link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20211001/entryDanishGAAPExcludingBalanceSheetIncomeStatementIncludingManagementsReview20211001.xsd"
xlink:type="simple"/>
<xbrli:context id="ctx-1">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-2">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>1</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-28">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-29">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-27">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-01-01</xbrli:startDate>
<xbrli:endDate>2020-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-30">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-31">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-32">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-33">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>4</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-34">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>5</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-35">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-01-01</xbrli:startDate>
<xbrli:endDate>2021-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>6</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<mrv:CorporateGovernanceReport contextRef="ctx-1" id="pp-value-11" xml:lang="en">BioPorto has a two-tiered management structure. In accordance with current practice in Denmark, responsibility is divided between the non-executive Board of Directors and the Executive Management Board, which are independent of each other. The Board of Directors determines the overall strategy and supervises BioPortoâs activities, management and organisation, while the Executive Management Board is in charge of the day-to-day management. Members of the Executive Management Board do not serve on the Board of Directors. The company's Board of Directors and Executive Management Board constantly strive to ensure transparency and accountability by building trusting relationships with shareholders, customers, suppliers, employees, and the local communities in which the company operates. As part of its management process, BioPorto focuses on investor relations, and the Board of Directors gives priority to exercising good corporate governance, which is defined based on the Companyâs Articles of Association, values and policies as well as relevant legislation and Nasdaq Copenhagen A/Sâ âNordic Main Market Rulebook for Issuers of Sharesâ. Recommendations for corporate governance BioPorto is subject to the Recommendations prepared by the Committee on Corporate Governance (the Recommendations), The Board of Directors regularly assesses how the Recommendations may contribute to strengthening the management of BioPorto and to ensuring value creation for the Companyâs shareholders. Once a year, the Board of Directors reviews the Recommendations and evaluates BioPortoâs compliance with the Recommendations. The Board of Directors believes that BioPorto has complied with all but four of the Recommendations. Work of the management and Board of Directors The Board of Directors defines BioPortoâs objectives, policies, and areas of activity. Furthermore, the Board of Directors makes decisions in all unusual matters or matters with far-reaching implications. In addition, the Board of Directors approves, monitors, evaluates and revises the Executive Managementâs business strategy and action plans. The Board of Directors also ensures that BioPorto is properly managed as required by the Articles of Association, other guidelines, policies and applicable rules and regulations. The Board of Directors defines guidelines for the distribution of responsibilities between the Board of Directors and the Executive Management but does not participate in the day-to-day management of the Company. The duties of the Board of Directors are described in the Rules of Procedure for the Board of Directors and the Executive Management. The Board of Directors held 15 Board meetings in 2021. Five meetings are planned for 2022 in accordance with the Board of Directorsâ annual schedule, which may be changed at any time to allow for additional meetings, if necessary. The Board of Directors appoints the Companyâs Executive Management and defines the working conditions and assignments to be undertaken by the Executive Management. BioPortoâs Executive Management is responsible to the Board of Directors for ensuring that the day-to-day operations are conducted in a commercially and legally responsible manner. Evaluation of the performance of the Board of Directors and the Executive Management The Chairman of the Board of Directors is responsible for evaluating the Board of Directors and the Executive Management every year. The evaluation also includes the collaboration with the Executive Management and the composition and special qualifications of the Board of Directors, and it must produce an assessment of the results achieved during the year, which are subsequently presented and discussed at a board meeting and accounted for in the management's review. Composition of the Board of Directors The General Meeting, which is BioPortoâs supreme authority, elects between three and seven members to the Board of Directors, and it currently consists of six members elected by the shareholders. The Board of Directors elects a Chairman and a Vice Chairman. Members elected by the shareholders hold office for terms of one year at a time and may be re-elected. The members of the Board are nominated and stand for election based on their specific qualifications and experience relevant to BioPorto. The Board of Directors is composed to ensure an optimal combination of industry experience and functional experience, including in research and development, IP rights and contracting, sales and marketing, as well as finance and economics. Not all current Board members are considered independent persons, but the Board of Directors can act independently. Board member Peter Mørch Eriksen is to be considered non-independent under the criteria defined by the Danish Committee on Corporate Governance. Each Board memberâs qualifications may be found on the Companyâs website:Board committees BioPortoâs Board of Directors has established the following Committees: Remuneration, Nomination, Audit Committee, Strategy, and Business, Research and Development. The Vice Chairman of the Board of Directors is Chairman of the Audit Committee and possesses the necessary professional qualifications and experience. A review of the terms of reference of the Board Committees and their composition is available on the Companyâs website. Amendments to the Articles of Association The general meeting adopts amendments to the Articles of Association and makes all other decisions based on a simple majority, provided that a specific majority or representation is not required pursuant to the provisions of the Danish Companies Act or the Articles of Association. </mrv:CorporateGovernanceReport>
<mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender contextRef="ctx-1" id="pp-value-128" xml:lang="en">Diversity in the composition of the Board is sought, with a reasonable age composition, several nationalities and an equal gender ratio. The Board currently has six members, all of whom are men. BioPorto has adopted a Diversity Policy that is available on the companyâs website and reads as follows: âBioPorto is committed to continue working towards ensuring and furthering equal opportunities for all employees in respect of differences, such as gender, age, religion, sexual orientation and ethnicity, as all â in our view â serve as key components in ensuring a better, more dynamic and healthier business. We believe that employees should be recognized because of â and not despite â their diversity. The view extended through this policy also includes maintaining equal opportunities for women and men at all management levels in the BioPorto group. The Board of Directors annually discusses the companyâs activities to ensure relevant diversity at management levels and evaluates the policy on diversity. BioPorto has defined a target, that no later than in 2022, at least 25% members of the Management of the company must be women. This target must not detract from other competency requirements in the nomination of members to the Management team of the company. With regards to diversity for the Board of Directors, the gender distribution is 100/0 at the end of 2021. As the defined target has not yet been reached, BioPorto will stay committed to reach the target within the set deadline.â The general meeting did not consider it necessary to change the existing board of directors at the general assembly or at the extraordinary general assembly last year. The nominating committee has a clear policy for evaluating candidates of both genders for vacant Board positions. For future vacant Board positions in 2022, the nomination committee will continue to evaluate candidates of both genders. Diversity in other layers of Management The company does not have a policy for diversity in other layers of Management, as the company is below the minimum threshold (cf. guidelines from the Danish Business Authority). Gender diversity in BioPorto The gender diversity in BioPorto at the end of 2021 is shown in the overview below: 2021 Female Male Board of Directors 0% 100% Executive Management (two persons) 0% 100% Management 60% 40% Other employees 65% 35% </mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender>
<mrv:StatementOfCorporateSocialResponsibility contextRef="ctx-1" id="pp-value-196" xml:lang="en">BioPorto is aware of its social responsibility and endeavors to improve its social and environmental conditions. In addition to the corporate social responsibility report provided below, BioPorto has signed on to the UN Global Compact, and the latest Communication on Progress,In several areas, BioPorto fulfils its responsibility solely by complying with current law, but in other areas, the companyâs responsibility has been expanded to include preventive activities for optimizing various conditions. It is important to BioPorto to highlight these efforts vis-Ã -vis its customers, suppliers, shareholders, other stakeholders, etc., to ensure that the outside world can have confidence in the company to live up to its social responsibility. For this reason, BioPorto continues its participation in the Global Compact, whose ten principles for social commitment as defined by the UN constitute a global frame of reference and are enumerated with commentary, below. At the same time, through our commitment, we will try to encourage the parties with whom we interact to consider and shoulder their share of these responsibilities. BioPortoâs business BioPortoâs business model seeks to utilize its unique library of monoclonal antibodies and its biomarker expertise to develop new clinical diagnostic products with attractive potential and bring them to the global market. The NGAL Test is an example of how BioPorto has successfully taken an antibody from research and discovery phase to a commercial clinical product. Starting with the development of unique monoclonal NGAL antibodies, it was transformed into a microtiter plate assay. From there BioPorto developed The NGAL Test into its current format for automated testing on clinical chemistry systems and is now sold directly and via partners to hospital central laboratories across the world. Risks The Groupâs risk of affecting the environment and climate, human rights, and anti-corruption is assessed to be limited. The risk assessment has been carried out in such a way that selected topics have been analyzed for their potential risk for BioPorto and the Groupâs stakeholders, respectively. Risk is in this context, a product of the subjectâs proportional role in the daily business, and the likely negative impact the topic has on the group or stakeholders. To the extent that risks have been identified, the individual areas are described together with the relevant policies. For a detailed description of BioPortoâs additional risks, see Risk management on page 17. Human rights 1. Businesses should support and respect the protection of internationally proclaimed human rights; and 2. make sure that they are not complicit in human rights abuses. BioPorto supports and respects internationally recognized human rights. It is imperative for BioPorto Our compliance in this area is broadly covered by our Code of Conduct as well as observance of the national labor and anti-discrimination laws in the countries in which we operate. In 2021, we have not received any reports of violation of human rights within our company. BioPortoâs employees are bound by BioPortoâs Code of Conduct and the company has initiated a process of implementing the Code of Conduct into supplier contracts to ensure that the companyâs suppliers respect human rights. BioPortoâs employees are trained on Human Rights and the Code of Conduct. We will continue in 2022 to have all new employees trained in human rights and the Code of Conduct. Also, we will in 2022 continue to conduct our clinical trials in a manner that recognizes the importance of respecting research participants while protecting their safety. We do this by applying good legal, ethical and scientific standards, in addition to complying with applicable laws and regulations. BioPortoâs Executive Management monitors and evaluates the performance annually. Any alleged incidents of human rights abuses would be reported to the Executive Management for prompt action. There were no incidents of human rights abuses reported to the Executive Management in 2021. BioPorto expects to maintain the same level of no incidents and efforts regarding human rights for 2022 as for 2021. Labor rights 3. Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining; 4. the elimination of all forms of forced and compulsory labor; 5. the effective abolition of child labor; and 6. the elimination of discrimination in respect of employment and occupation. Danish and American traditions, culture and law mean that labor rights are supported and complied with by BioPorto in Denmark and the United States. BioPorto has no external suppliers in countries that use child labor or forced and compulsory labor, and BioPorto deems that there is a very low risk of this taking place in areas where BioPorto might be expected to operate. In 2017, BioPorto established a Code of Conduct covering the above. BioPortoâs employees are bound by BioPortoâs Code of Conduct and the company has initiated a process of implementing the Code of Conduct into supplier contracts to ensure that suppliers comply with these labor rights. BioPorto actively supports and respects human rights, labor standards and provides a safe and healthy working environment for the staff that includes opportunities for professional and personal development. The BioPorto Group has fair and equal employment terms and working conditions, including equality and non-discrimination. BioPortoâs employee handbook covers policies concerning the employee rights. BioPorto considers employee safety and health to be of the highest priority. BioPorto works consistently to maintain a safe and healthy work environment with many procedures in place. Both the physical and mental working environments are monitored and continually improved to avoid accidents, injury and illness. Management ensures that employees also in 2022 are trained to handle hazardous goods and chemicals correctly. In the composition of its staff, BioPorto endeavours to achieve an equal gender breakdown as well as a diversity of educational backgrounds, nationalities and cultures. This diversity provides a dynamic work environment and encourages collaboration to the benefit of the staff and company efforts alike. Any incidents of violations of labor principles would be reported to the Executive Management which would investigate the violation. BioPorto monitors and evaluates performance yearly by looking at work related injuries and employee related cases with unions. BioPorto had zero employee related cases with unions in 2021, and BioPorto had no work related injuries in 2021. BioPorto expects to maintain the same level of no Work-related injuries and efforts regarding labor rights for 2022 as for 2021. Environment 7. Businesses should support a precautionary approach to environmental challenges; 8. undertake initiatives to promote greater environmental responsibility; and 9. encourage the development and diffusion of environmentally friendly technologies. BioPortoâs in-house production is limited in scope and of such a nature that it has an insignificant environmental impact. BioPorto is committed to full compliance with all environmental laws, standards and guidelines in the jurisdictions where it operates and continuously seek to reduce its environmental impact as much as possible. An ongoing effort will be made in an environmentally conscious way to minimize any other possible environmental impact, including the consumption of water and electricity, which will cut costs at the same time. BioPortoâs activities are primarily knowledge-based, and employees are encouraged to be mindful of the environment and climate, and to produce as little waste as possible. Employees are bound by BioPortoâs Code of Conduct and the company has initiated a process of implementing the Code of Conduct into supplier contracts to ensure the above. As in 2021, BioPorto continues to consume less paper by encouraging electronic copies and double-sided printing when hard copies are necessary. Management will continually in 2022 to encourage employees to embrace environmental and climate friendly initiatives as BioPorto aim to reduce BioPortoâs environmental footprint. Any environmental incident would be reported to the executive management team, and they would take prompt action to make sure the incident would not happen again. BioPorto expects to maintain the same level of no incidents and efforts regarding enviroment for 2022 as for 2021. Anti-corruption 10. Businesses should work against corruption in all its forms, including extortion and bribery. BioPorto has a zero-tolerance policy regarding corruption, bribery, and similar methods.BioPortoâs activities must always be in compliance with all required country anti-corruption legislation and the UN Convention against Corruption. Suppliers and partners are chosen with care and are included in BioPortoâs quality system. Corruption problems have not affected BioPortoâs activities up to now and BioPorto has not been involved in any legal cases, rulings or other events related to corruption or bribery. BioPorto does not permit or participate in money laundering. In 2017, BioPorto established a Code of Conduct covering the above. Employees are bound by the Code of Conduct and the company has initiated a process of implementing the Code of Conduct into supplier contracts to ensure that suppliers comply with the above. In 2021 all new employees received training as part of their introductory program regarding anti-corruption and the Code of Conduct and BioPorto will maintain the same level of training in 2022. Any incidents of corruption would be reported to the executive management, and they would prompt take action to ensure that a similar incident would not happen again. BioPorto expects to maintain the same level of no incidents and efforts regarding anti-corruption for 2022 as for 2021. Privacy and GDPR (G) BioPorto focus on privacy and protection of personal data throughout BioPorto, covering the data of employees, partners, and other stakeholders. BioPorto has implemented strong measures to protect personal data and complies with the EU General Data Protection Regulation (GDPR) and national personal data protection legislation. All new employees received GDPR and data training as part of their introductory program in 2021. I 2022 BioPorto will keep the same level of effort to secure that BioPorto complies with the above-mentioned policies and new employees receive the training in GDPR and data. </mrv:StatementOfCorporateSocialResponsibility>
<mrv:StatementOfPolicyForDataEthics contextRef="ctx-1" id="pp-value-411" xml:lang="en">BioPorto has in 2021 implemented a Data Ethics Policy. In this policy, BioPortoâs approach to data ethics is defined pursuant to section 99 d of the Danish Financial Statements Act. </mrv:StatementOfPolicyForDataEthics>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx-1" id="pp-value-421" xml:lang="en"> Tuborg Havnevej </gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx-1" id="pp-value-422" xml:lang="en"> 15,</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:AddressOfReportingEntityCountryIdentificationCode contextRef="ctx-1" id="pp-value-423" xml:lang="en">DK </gsd:AddressOfReportingEntityCountryIdentificationCode>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" id="pp-value-424" xml:lang="en"> 2900 </gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx-1" id="pp-value-425" xml:lang="en"> Hellerup.</gsd:AddressOfReportingEntityDistrictName>
<gsd:NameOfLawFirm contextRef="ctx-1" xml:lang="en">Gorrissen Federspiel </gsd:NameOfLawFirm>
<gsd:AddressOfLawFirmStreetName contextRef="ctx-1" xml:lang="en">Axeltorv </gsd:AddressOfLawFirmStreetName>
<gsd:AddressOfLawFirmStreetBuildingIdentifier contextRef="ctx-1" id="pp-value-428" xml:lang="en"> 2 </gsd:AddressOfLawFirmStreetBuildingIdentifier>
<gsd:AddressOfLawFirmCountry contextRef="ctx-1" id="pp-value-429" xml:lang="en">DK </gsd:AddressOfLawFirmCountry>
<gsd:AddressOfLawFirmPostCodeIdentifier contextRef="ctx-1" id="pp-value-430" xml:lang="en"> 1609 </gsd:AddressOfLawFirmPostCodeIdentifier>
<gsd:AddressOfLawFirmDistrictName contextRef="ctx-1" id="pp-value-431" xml:lang="en"> København V </gsd:AddressOfLawFirmDistrictName>
<gsd:AddressOfAuditorStreetName contextRef="ctx-2" xml:lang="en">Strandvejen </gsd:AddressOfAuditorStreetName>
<gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx-2" id="pp-value-433" xml:lang="en"> 44 </gsd:AddressOfAuditorStreetBuildingIdentifier>
<gsd:AddressOfAuditorCountry contextRef="ctx-2" id="pp-value-434" xml:lang="en">DK </gsd:AddressOfAuditorCountry>
<gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx-2" id="pp-value-435" xml:lang="en"> 2900 </gsd:AddressOfAuditorPostCodeIdentifier>
<gsd:AddressOfAuditorDistrictName contextRef="ctx-2" id="pp-value-436" xml:lang="en"> Hellerup </gsd:AddressOfAuditorDistrictName>
<gsd:NameOfReportingEntity contextRef="ctx-1" xml:lang="en">BioPorto A/S,</gsd:NameOfReportingEntity>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-28" xml:lang="en">Anthony Paul Pare </cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-29" xml:lang="en">Neil Allan Goldman </cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx-28" id="pp-value-441" xml:lang="en"> CEO </cmn:TitleOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx-29" xml:lang="en"> EVP & CFO i</cmn:TitleOfMemberOfExecutiveBoard>
<fsa:AverageNumberOfEmployees contextRef="ctx-1" decimals="0" unitRef="pure">29</fsa:AverageNumberOfEmployees>
<fsa:AverageNumberOfEmployees contextRef="ctx-27" decimals="0" unitRef="pure">28</fsa:AverageNumberOfEmployees>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx-1" id="pp-value-445" xml:lang="en">The Board of Directors and Executive Management have today considered and adopted the Annual Report of BioPorto A/S for the financial year January 1 â December 31, 2021. The Consolidated Financial Statements have been prepared in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act, and the Parent Company Financial Statements have been prepared in accordance with the Danish Financial Statements Act. Managementâs Review has been prepared in accordance with the Danish Financial Statements Act. In our opinion, the Consolidated Financial Statements and the Parent Company Financial Statements give a true and fair view of the financial position at December 31, 2021 of the Group and the Parent Company and of the results of the Group and Parent Company operations and consolidated cash flows for the financial year January 1 - December 31, 2021. In our opinion, Managementâs Review includes a true and fair account of the development in the operations and financial circumstances of the Group and the Parent Company, of the results for the year and of the financial position of the Group and the Parent Company as well as a description of the most significant risks and elements of uncertainty facing the Group and the Parent Company. In our opinion, the Annual Report of the Group and the Parent Company for the financial year 1 January to 31 December 2021, identified as 5299004SWFL5JAN4W830-2021-12-31-en.zip, has been prepared, in all material respects, in compliance with the ESEF Regulation. We recommend that the Annual Report be adopted at the Annual General Meeting. </sob:StatementByExecutiveAndSupervisoryBoards>
<sob:PlaceOfSignatureOfStatement contextRef="ctx-1" id="pp-value-470" xml:lang="en">Hellerup,</sob:PlaceOfSignatureOfStatement>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx-1" id="pp-value-471" xml:lang="en">2022-04-06</sob:DateOfApprovalOfAnnualReport>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-30" id="pp-value-472" xml:lang="en">Christopher Lindop </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-30" id="pp-value-473" xml:lang="en">Chairman </cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-31" id="pp-value-474" xml:lang="en">John McDonough </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-31" xml:lang="en">Vice Chairman </cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-32" id="pp-value-476" xml:lang="en">Michael Singer </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-33" id="pp-value-477" xml:lang="en">Jan Leth Christensen </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-34" xml:lang="en">Don Hardison </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-35" id="pp-value-479" xml:lang="en">Peter Mørch Eriksen </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">To the shareholders of BioPorto A/S </arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-481" xml:lang="en"> opinion In our opinion, the Consolidated Financial Statements give a true and fair view of the Groupâs financial position at 31 December 2021 and of the results of the Groupâs operations and cash flows for the financial year 1 January to 31 December 2021 in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act. Moreover, in our opinion, the Parent Company Financial Statements give a true and fair view of the Parent Companyâs financial position at 31 December 2021 and of the results of the Parent Companyâs operations for the financial year 1 January to 31 December 2021 in accordance with the Danish Financial Statements Act. Our opinion is consistent with our Auditorâs Long-form Report to the Audit Committee and the Board of Directors. What we have audited The Consolidated Financial Statements and Parent Company Financial Statements of BioPorto A/S for the financial year 1 January to 31 December 2021 comprise income statement, balance sheet, statement of changes in equity and notes, including summary of significant accounting policies for the Group as well as for the Parent Company and statement of comprehensive income and cash flow statement for the Group. Collectively referred to as the âFinancial Statementsâ. </arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx-1" id="pp-value-501" xml:lang="en">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the Financial Statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Independence We are independent of the Group in accordance with the International Ethics Standards Board for Accountantsâ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark. We have also fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. To the best of our knowledge and belief, prohibited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014 were not provided. Appointment We were first appointed auditors of BioPorto A/S on 10 April 2014 for the financial year 2014. We have been reappointed annually by shareholder resolution for a total period of uninterrupted engagement of 8 years including the financial year 2021. </arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:KeyAuditMattersAudit contextRef="ctx-1" xml:lang="en">We have determined that there are no key audit matters to communicate in our report. </arr:KeyAuditMattersAudit>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-523" xml:lang="en">Management is responsible for Managementâs Review. Our opinion on the Financial Statements does not cover Managementâs Review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the Financial Statements, our responsibility is to read Managementâs Review and, in doing so, consider whether Managementâs Review is materially inconsistent with the Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. Moreover, we considered whether Managementâs Review includes the disclosures required by the Danish Financial Statements Act. Based on the work we have performed, in our view, Managementâs Review is in accordance with the Consolidated Financial Statements and the Parent Company Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Managementâs Review. </arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx-1" id="pp-value-536" xml:lang="en">Management is responsible for the preparation of consolidated financial statements and parent company financial statements that give a true and fair view in accordance with International Financial Reporting Standards as adopted by the EU and further requirements in the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the Financial Statements, Management is responsible for assessing the Groupâs and the Parent Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Management either intends to liquidate the Group or the Parent Company or to cease operations, or has no realistic alternative but to do so. </arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx-1" id="pp-value-547" xml:lang="en">Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements. As part of an audit in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also: â Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. â Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Groupâs and the Parent Companyâs internal control. â Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management. â Conclude on the appropriateness of Managementâs use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Groupâs and the Parent Companyâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Group or the Parent Company to cease to continue as a going concern. â Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that gives a true and fair view. â Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and, where applicable, actions taken to eliminate threats or safeguards applied. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditorâs report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication. </arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:AuditorsReportOnXbrlTagging contextRef="ctx-1" id="pp-value-603" xml:lang="en">As part of our audit of the Financial Statements we performed procedures to express an opinion on whether the annual report of BioPorto A/S for the financial year 1 January to 31 December 2021 with the filename 5299004SWFL5JAN4W830-2021-12-31-en.zip is prepared, in all material respects, in compliance with the Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation) which includes requirements related to the preparation of the annual report in XHTML format and iXBRL tagging of the Consolidated Financial Statements. Management is responsible for preparing an annual report that complies with the ESEF Regulation. This responsibility includes: â The preparing of the annual report in XHTML format; â The selection and application of appropriate iXBRL tags, including extensions to the ESEF taxonomy and the anchoring thereof to elements in the taxonomy, for all financial information required to be tagged using judgement where necessary; â Ensuring consistency between iXBRL tagged data and the Consolidated Financial Statements presented in human-readable format; and â For such internal control as Management determines necessary to enable the preparation of an annual report that is compliant with the ESEF Regulation. Our responsibility is to obtain reasonable assurance on whether the annual report is prepared, in all material respects, in compliance with the ESEF Regulation based on the evidence we have obtained, and to issue a report that includes our opinion. The nature, timing and extent of procedures selected depend on the auditorâs judgement, including the assessment of the risks of material departures from the requirements set out in the ESEF Regulation, whether due to fraud or error. The procedures include: â Testing whether the annual report is prepared in XHTML format; â Obtaining an understanding of the companyâs iXBRL tagging process and of internal control over the tagging process; â Evaluating the completeness of the iXBRL tagging of the Consolidated Financial Statements; â Evaluating the appropriateness of the companyâs use of iXBRL elements selected from the ESEF taxonomy and the creation of extension elements where no suitable element in the ESEF taxonomy has been identified; â Evaluating the use of anchoring of extension elements to elements in the ESEF taxonomy; and â Reconciling the iXBRL tagged data with the audited Consolidated Financial Statements. In our opinion, the annual report of BioPorto A/S for the financial year 1 January to 31 December 2021 with the file name 5299004SWFL5JAN4W830-2021-12-31-en.zip is prepared, in all material respects, in compliance with the ESEF Regulation. </arr:AuditorsReportOnXbrlTagging>
<arr:SignatureOfAuditorsPlace contextRef="ctx-1" id="pp-value-641" xml:lang="en">Hellerup,</arr:SignatureOfAuditorsPlace>
<arr:SignatureOfAuditorsDate contextRef="ctx-1" id="pp-value-642" xml:lang="en">2022-04-06</arr:SignatureOfAuditorsDate>
<cmn:NameOfAuditFirm contextRef="ctx-2" id="pp-value-643" xml:lang="en">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab </cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-2" xml:lang="en">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-2" xml:lang="en">Mads Melgaard </cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-2" xml:lang="en">State Authorised Public Accountant </cmn:DescriptionOfAuditor>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1" xml:lang="en">17500317</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1" xml:lang="en">Annual report</gsd:InformationOnTypeOfSubmittedReport>
<cmn:TypeOfAuditorAssistance contextRef="ctx-1" xml:lang="en">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
<gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx-1" xml:lang="en">ParsePort XBRL Converter</gsd:ToolForPreparingTheXBRLInstanceDocument>
<gsd:ReportingPeriodStartDate contextRef="ctx-1" xml:lang="en">2021-01-01</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx-1" xml:lang="en">2021-12-31</gsd:ReportingPeriodEndDate>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx-1" xml:lang="en">2020-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx-1" xml:lang="en">2020-12-31</gsd:PredingReportingPeriodEndDate>
<gsd:LegalEntityIdentifierOfReportingEntity contextRef="ctx-1" xml:lang="en">5299004SWFL5JAN4W830</gsd:LegalEntityIdentifierOfReportingEntity>
<fsa:ClassOfReportingEntity contextRef="ctx-1" xml:lang="en">Reporting class D</fsa:ClassOfReportingEntity>
<gsd:LegalEntityIdentifierOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">5299004SWFL5JAN4W830</gsd:LegalEntityIdentifierOfSubmittingEnterprise>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">17500317</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:NameOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">BioPorto A/S</gsd:NameOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" xml:lang="en">Tuborg Havnevej 15</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" xml:lang="en">2900 Hellerup</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
<arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-2" xml:lang="en">mne34354</cmn:IdentificationNumberOfAuditor>
</xbrli:xbrl>